Humacyte Wins Surgical Implant Contract for Symvess Across 170 VA Hospitals
HUMA•Humacyte’s Symvess vascular repair product secured a Surgical Implant – Next Generation contract with the VA’s Strategic Acquisition Center, granting access to 170 VA hospitals. The contract’s vetting by a surgical committee and streamlined hospital approvals should accelerate Symvess adoption and potential revenue growth within the VA system.
1. SAC Contract Award
Humacyte announced that Symvess has been awarded a Surgical Implant – Next Generation contract by the VA’s Strategic Acquisition Center (SAC). This contract designates SAC as the primary sourcing vehicle for Symvess, covering procurement for all 170 VA hospitals in the national system.
2. Distribution and Commercial Implications
SAC awards involve rigorous vetting by a surgical committee and unify contract terms across hospitals, eliminating individual hospital negotiations. This streamlined process enables quicker product adoption, potentially boosting sales and market penetration within the VA healthcare network.
3. Symvess Product Profile
Symvess received FDA approval in December 2024 for extremity vascular trauma and remains investigational for other indications. Ongoing late-stage trials target arteriovenous access for hemodialysis and peripheral artery disease, expanding the product’s long-term addressable market.
